cas 22621-41-6|| where to buy Methyl 2-hydroxy-3-nitrobenzoate

Product Name:Methyl 2-hydroxy-3-nitrobenzoate

IUPAC Name:methyl 2-hydroxy-3-nitrobenzoate

Packing Unit	Available Stock	Price($)
CM157013-500g	in stock	Ĳƿƥ
CM157013-1000g	in stock	ŤǙŮȃ

For R&D use only.

Inquiry Form

Chemical Name

CAS Number

Quantity*

Required Specifications*
(Assay %, Material Grade etc.)

Contact Name*

Contact Email*

Meanwhile I'd like to create a registered account on CHEMENU.COM with the above email.

I'd like to receive emails related to products with similar structures to 22621-41-6 regularly via the above email.

Additional Notes

Verification code*

refresh

: CAS NO:22621-41-6; Molecular Formula:C8H7NO5; Melting Point:-; Smiles Code:O=C(OC)C1=CC=CC([N+]([O-])=O)=C1O; Density:

: Catalog Number:CM157013; Molecular Weight:197.15; Boiling Point:263.9°C at 760 mmHg; MDL No:MFCD00272263; Storage:Keep in a tight container filled with nitrogen and store at ambient temperature，protect from light

: Benzenes; Benzene is an important organic compound with the chemical formula C6H6, and its molecule consists of a ring of 6 carbon atoms, each with 1 hydrogen atom. Benzene is a sweet, flammable, colorless and transparent liquid with carcinogenic toxicity at room temperature, and has a strong aromatic odor. It is insoluble in water, easily soluble in organic solvents, and can also be used as an organic solvent itself. The ring system of benzene is called benzene ring, and the structure after removing one hydrogen atom from the benzene ring is called phenyl. Benzene is one of the most important basic organic chemical raw materials. Many important chemical intermediates can be derived from benzene through substitution reaction, addition reaction and benzene ring cleavage reaction.

: Deucravacitinib; BMY announced new four-year Sotyktu (deucravacitinib) data demonstrating durable response rates and consistent safety in moderate-to-severe plaque psoriasis. Deucravacitinib is a specific, oral, intracellular TYK2 inhibitor that targets immune responses driven by type 1 IFN and IL-23 that contribute to psoriasis pathogenesis, including IL-17 production and Th1/Th17 polarization.